A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma
by on Tuesday, August 28th, 2012 | No Comments
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Tivozanib Hydrochloride; Drug: Sunitinib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.; Astellas Pharma Inc
Recruiting – verified August 2012
Go here to see the original: A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma